• Client Login
Ozmosi
  • Services
    • BEAM Clinical Trial Data
    • GCT Global Clinical Trials
    • PRYZM Pharma Product Database
    • KRYSTL Industry Scan Reporting
    • LENZ Company Pipeline Summary
    • Specialized Consulting
    • Approved Pharmaceutical Products in Use
  • About Us
  • Case Studies
  • Newsroom
  • Contact Us
Select Page
Novo Nordisk Diabetes Pipeline Analysis

Novo Nordisk Diabetes Pipeline Analysis

Oct 19, 2017 | Chronic Disease, Diabetes, Disease Area Trends

Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog®  and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...

Recent Posts

  • Healthiest States Index of The USA 2023May 8, 2023
  • FDA Accelerated Approval, Breakthrough Therapy, and Fast Track Designations Supercharge Drug DevelopmentMarch 9, 2023
  • Using Data to Optimize Clinical Trial RecruitmentJanuary 23, 2023
  • Uncovering New Catalyst Events in the Pharmaceutical and Biotech MarketsNovember 11, 2022
  • New Developments in Alzheimer’s TreatmentOctober 7, 2022
  • The Clinical Trial PowershiftSeptember 19, 2022
  • Home
  • About Us
  • Services
  • Case Studies
  • Newsroom
  • Contact Us
  • Facebook
  • Twitter
OZMOSI© 2023 | All Rights Reserved | Site by Webtyde